CN115868631A - Composition for promoting intestinal health and application and product thereof - Google Patents
Composition for promoting intestinal health and application and product thereof Download PDFInfo
- Publication number
- CN115868631A CN115868631A CN202211630783.2A CN202211630783A CN115868631A CN 115868631 A CN115868631 A CN 115868631A CN 202211630783 A CN202211630783 A CN 202211630783A CN 115868631 A CN115868631 A CN 115868631A
- Authority
- CN
- China
- Prior art keywords
- oligosaccharide
- composition
- cells
- adhesion
- fucosyllactose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000001737 promoting effect Effects 0.000 title claims abstract description 12
- 230000007413 intestinal health Effects 0.000 title abstract description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 46
- 150000003271 galactooligosaccharides Chemical class 0.000 claims abstract description 46
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims abstract description 44
- HWHQUWQCBPAQQH-BWRPKUOHSA-N 2-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O HWHQUWQCBPAQQH-BWRPKUOHSA-N 0.000 claims abstract description 40
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 40
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 40
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 40
- 229940062827 2'-fucosyllactose Drugs 0.000 claims abstract description 38
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims abstract description 38
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims abstract description 38
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims abstract description 37
- 239000006041 probiotic Substances 0.000 claims abstract description 37
- 235000018291 probiotics Nutrition 0.000 claims abstract description 37
- 229940107187 fructooligosaccharide Drugs 0.000 claims abstract description 35
- 235000013305 food Nutrition 0.000 claims abstract description 8
- 230000000968 intestinal effect Effects 0.000 claims abstract description 4
- 241000894006 Bacteria Species 0.000 claims description 29
- 230000000529 probiotic effect Effects 0.000 claims description 21
- 235000013350 formula milk Nutrition 0.000 claims description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- 239000002417 nutraceutical Substances 0.000 claims 2
- 235000021436 nutraceutical agent Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002474 experimental method Methods 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 4
- 235000021107 fermented food Nutrition 0.000 abstract description 2
- 235000019722 synbiotics Nutrition 0.000 abstract description 2
- 229920001542 oligosaccharide Polymers 0.000 description 55
- 150000002482 oligosaccharides Chemical class 0.000 description 51
- 239000001963 growth medium Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 18
- 239000000725 suspension Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000000855 fermentation Methods 0.000 description 12
- 230000004151 fermentation Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000002356 single layer Substances 0.000 description 6
- 230000021164 cell adhesion Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- -1 compound oligosaccharide Chemical class 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000003352 cell adhesion assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a composition for promoting intestinal health, and application and a product thereof. According to the composition, fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose are compounded according to a specific proportion, and the formed composition can remarkably improve the adhesion capability of probiotics to Caco-2 cells, so that the colonization of the probiotics in intestinal tracts is enhanced. Experiments show that the composition can improve the adhesion capacity of lactobacillus plantarum AUH2103 to Caco-2 cells by 370-430 times, and improve the adhesion capacity of lactobacillus rhamnosus MP108 to Caco-2 cells by 9-14 times, which indicates that the composition can effectively promote intestinal colonization of probiotics and promote intestinal health, and is suitable for preparation of synbiotic foods and fermented foods.
Description
Technical Field
The invention relates to the technical field of food biotechnology, in particular to a composition for promoting intestinal health and application and a product thereof.
Background
After passing through the gastrointestinal tract, probiotics reach the intestinal tract in a certain amount, and the adhesion on the intestinal mucosa is an important precondition for the physiological action of the probiotics; furthermore, this adhesion is a prerequisite for many probiotic effects exerted by probiotics, and therefore the ability of probiotics to adhere to the intestinal tract is an important indicator for evaluating the probiotic ability of probiotics.
The probiotics and the prebiotics have synergistic effect, the prebiotics and the probiotics are added simultaneously in the infant formula food in China to enhance the prebiotics effect, and the most used oligosaccharides are fructo-oligosaccharide (FOS) and galacto-oligosaccharide (GOS); in addition, with the continuous progress of chemical and biological synthesis technology, 2 '-fucosyllactose (2' -FL) is the only breast milk oligosaccharide which can be industrially produced at present, and is approved by FDA and European Union in 2015 and 2016 to become a legal component of infant formula. However, the effect of the existing prebiotic composition and probiotic combination products in improving the intestinal health is still not ideal.
Disclosure of Invention
In view of the above, the invention provides a composition for promoting intestinal health, and applications and products thereof. The composition can remarkably improve the adhesion capability of probiotics on Caco-2 cells, thereby enhancing the colonization of the probiotics in the intestinal tract and promoting the intestinal health.
In order to achieve the above object, the present invention provides the following technical solutions:
a composition comprising fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose. Wherein the mass ratio of the fructo-oligosaccharide, the galacto-oligosaccharide and the 2' -fucosyllactose is (1-10) to (1-4).
In some embodiments, the mass ratio of fructooligosaccharide, galactooligosaccharide, and 2' -fucosyllactose is 1.
In some embodiments, the compositions provided herein further comprise a probiotic, i.e., the composition consists of fructooligosaccharides, galactooligosaccharides, 2' -fucosyllactose, and a probiotic. Wherein the probiotic bacteria comprise lactobacillus rhamnosus and/or lactobacillus plantarum.
In some embodiments, the composition consists of fructooligosaccharides, galactooligosaccharides, 2' -fucosyllactose, and lactobacillus rhamnosus.
In some embodiments, the composition consists of fructooligosaccharides, galactooligosaccharides, 2' -fucosyllactose, and lactobacillus plantarum.
In the composition, the sources of the strains of the lactobacillus rhamnosus and the lactobacillus plantarum are not particularly limited, and the strains can be common commercial products in the field and can also be collected and separated by self. In some embodiments of the invention, the lactobacillus rhamnosus is the lactobacillus rhamnosus MP108 strain and the lactobacillus plantarum is the lactobacillus plantarum AUH2103 strain.
The invention also provides application of the composition in preparing a product for promoting intestinal health and improving intestinal probiotic colonization; the probiotics comprise at least one of lactobacillus rhamnosus and lactobacillus plantarum.
In the application, the composition can improve the adhesion capacity of probiotics to Caco-2 cells; can improve the adhesion capacity of the lactobacillus plantarum AUH2103 to Caco-2 cells by 370-430 times, and improve the adhesion capacity of the lactobacillus rhamnosus MP108 to the Caco-2 cells by 9-14 times.
In the application of the invention, the product comprises infant formula milk powder, infant formula food, formula food for special medical application, nutritional health food, probiotic solid beverage and fermented product.
The invention also provides a product for promoting intestinal health, which comprises the composition disclosed by the invention and raw and auxiliary materials acceptable to food and/or health-care products.
In some embodiments, the product is an infant formula, the composition consists of lactobacillus plantarum, which is lactobacillus plantarum AUH2103 strain, fructooligosaccharide, galactooligosaccharide, and 2' -fucosyllactose. The viable count of Lactobacillus plantarum AUH2103 is preferably 1 × 10 6 -1×10 7 CFU/g; the mass ratio of the fructo-oligosaccharide, the galacto-oligosaccharide and the 2' -fucosyllactose is (1-4) and is 1. The total amount of the above three oligosaccharides added per 100g milk powder is preferably 4-8g, specifically 4g, 5g, 6g, 7g, and 8g.
In some embodiments, the product is an infant formula and the composition consists of lactobacillus rhamnosus, fructo-oligosaccharides, galacto-oligosaccharides and 2' -fucosyllactose, the lactobacillus rhamnosus being a lactobacillus rhamnosus MP108 strain. Wherein the number of viable bacteria of Lactobacillus rhamnosus MP108 is preferably 1 × 10 6 -1×10 7 CFU/g; the mass ratio of the fructo-oligosaccharide to the galacto-oligosaccharide to the 2' -fucosyllactose is (1-4): 1, and specifically can be 10. The total amount of the above three oligosaccharides added per 100g milk powder is preferably 4-8g, specifically 4g, 5g, 6g, 7g, and 8g.
In some embodiments, the product is a probiotic solid beverage, the composition consists of lactobacillus plantarum, which is a strain of lactobacillus plantarum AUH2103, fructo-oligosaccharide, galacto-oligosaccharide, and 2' -fucosyllactose. Wherein the viable count of the lactobacillus plantarum AUH2103 is preferably 1 × 108-1 × 109CFU/g; the mass ratio of the fructo-oligosaccharide, the galacto-oligosaccharide and the 2' -fucosyllactose is (1-4) and is 1 (1-4), and the mass ratio can be 4. The total amount of the above three oligosaccharides is preferably 0.4-0.6g, specifically 0.4g, 0.5g, and 0.6g, per 100g milk powder.
In some embodiments, the product is a probiotic solid beverage, the composition consists of lactobacillus rhamnosus, fructo-oligosaccharides, galacto-oligosaccharides and 2' -fucosyllactose, the lactobacillus rhamnosus being a lactobacillus rhamnosus MP108 strain. Wherein the number of viable bacteria of Lactobacillus rhamnosus MP108 is preferably 1 × 10 8 -1×10 9 CFU/g; the mass ratio of fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose is (1-4) 1, specifically 10. The total amount of the above three oligosaccharides added to 100g milk powder is preferably 4-8g, specifically 4g, 5g, 6g, 7g, and 8g.
According to the composition, fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose are compounded according to a specific proportion, and the formed composition can remarkably improve the adhesion capability of probiotics to Caco-2 cells, so that the colonization of the probiotics in intestinal tracts is enhanced. Experiments show that the composition can improve the adhesion capacity of lactobacillus plantarum AUH2103 to Caco-2 cells by 370-430 times and improve the adhesion capacity of lactobacillus rhamnosus MP108 to Caco-2 cells by 9-14 times, which indicates that the composition can effectively promote intestinal colonization of probiotics and promote intestinal health, and is suitable for preparation of synbiotic foods and fermented foods.
Detailed Description
The invention provides a composition for promoting intestinal health, and application and a product thereof. Those skilled in the art can modify the process parameters appropriately to achieve the desired results with reference to the disclosure herein. It is specifically noted that all such substitutions and modifications will be apparent to those skilled in the art and are intended to be included herein. While the methods and applications of this invention have been described in terms of preferred embodiments, it will be apparent to those of ordinary skill in the art that variations and modifications in the methods and applications described herein, as well as other suitable variations and combinations, may be made to implement and use the techniques of this invention without departing from the spirit and scope of the invention.
The test materials adopted by the invention are all common commercial products and can be purchased in the market.
The invention is further illustrated by the following examples:
example 1 Complex oligosaccharide combination for improving adhesion of Lactobacillus plantarum AUH2103 to Caco-2 cells
1.1 Strain activation:
the lactobacillus plantarum AUH2103 was stored in a freeze-dried powder state before the experiment. In the experiment, the strain is inoculated in MRS liquid culture medium for activation, and then is separated and purified on an MRS-agar plate and is preserved by using a glycerol method. Activation from glycerol storage tubes was done before each experiment.
1.2 culture Medium
Culture medium A: the culture medium of glucose in MRS is replaced by oligosaccharide, and the concentrations of oligosaccharide in the culture medium are respectively as follows: fructo-oligosaccharide (MRS-FOS) 40g/L, galacto-oligosaccharide (MRS-GOS) 20g/L, 2 '-fucosyllactose (MRS-2' -FL) 20 g/L;
and (3) a culture medium B: adding oligosaccharide into MRS, wherein the respective concentrations of the oligosaccharide in a culture medium are as follows: 40g/L fructo-oligosaccharide (MRS-FOS), 20g/L galacto-oligosaccharide (MRS-GOS), and 20 g/L2 '-fucosyllactose (MRS-2' -FL).
1.3 preparation of strain suspension:
adding oligosaccharide before fermentation: after the strain is activated, the strain is respectively inoculated into a culture medium A and a culture medium B according to the inoculation amount of 3 percent, an MRS culture medium is used as a control group, after 18 hours of culture, the strain is collected by centrifugation (10000 r/min,2 min), and is washed three times by PBS. Finally, resuspend with PBS and perform adhesion test.
Adding oligosaccharide after fermentation: after the strain is activated, the strain is inoculated in MRS culture medium according to the inoculation amount of 3 percent, after being cultured for 18 hours, the strain is collected by centrifugation (10000 r/min,2 min), and is washed 3 times by PBS. Finally, fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose with different concentrations or oligosaccharide combinations with different proportions are respectively added during the heavy suspension by PBS, and the order of magnitude of the viable bacteria number is adjusted to 10 9 CFU/mL, adhesion test.
1.4 cell adhesion assay:
human colorectal adenocarcinoma cells Caco-2 are preserved in liquid nitrogen, passage is carried out after activation, when the cells are stable, the Caco-2 cells are cultured until a compact single-layer membrane is formed, the cell shape is good, the boundary is clear,used for adhesion tests. Caco-2 cells were cultured at 2X 10 5 The concentration of individual cells/well was seeded in 24-well cell culture plates at 5% CO 2 And 95% relative humidity at 37 ℃ until a monolayer of cells is formed. The monolayer cells were washed 2 times with PBS (pH 7.2) and 500. Mu.L of a lactic acid bacteria suspension (adjusted to a viable count of the order of 10) was added to each well 9 CFU/mL), 5% CO at 37 deg.C 2 And 95% relative humidity for 2h. The membrane was washed 3 times with PBS (pH 7.2) to remove unbound bacteria, 150. Mu.L of 0.25% trypsin digest was added, and after 15min of digestion at 37 ℃, 350. Mu.L of MEM medium supplemented with 10% fetal bovine serum was added to each well to stop digestion. Continuously diluting the mixture by 10 times of gradient, and detecting the number of viable bacteria by adopting a flat plate colony counting method, wherein the counted number of viable bacteria is the number of bacteria adhered to cells, and the number can reflect the strength of the adhesion capability of the bacteria to the cells under the condition that the number of the cells is the same.
1.5 Effect of oligosaccharide addition before fermentation on the adherence of Lactobacillus plantarum AUH2103 to Caco-2 cells
Lactobacillus plantarum AUH2103 thalli cultured in different oligosaccharide MRS culture media are collected to prepare bacterial suspension, and the adhesion capability of the bacterial suspension to Caco-2 cells is measured, and the results are shown in Table 1.
TABLE 1 Effect of oligosaccharide addition before fermentation on the cell adhesion of Lactobacillus plantarum AUH2103
Note: different superscript letters in the same column indicate significant differences (P < 0.05);
* The initial viable count of MRS-2' -FL group cannot reach 10 9 CFU/mL。
As can be seen from Table 1, the viable count of Lactobacillus plantarum AUH2103 after all groups had adhered Caco-2 cells was 10 5 On the order of CFU/mL. In the three experimental groups added with oligosaccharide, the number of viable bacteria after adhesion is obviously smaller than that of an MRS control group, and the experimental results show that the oligosaccharide cannot be added or replaced before fermentationEffectively improve the adhesion capability of the lactobacillus plantarum AUH2103 to Caco-2 cells.
1.6 Effect of oligosaccharide addition on Lactobacillus plantarum AUH2103 adhesion to Caco-2 cells during incubation
In order to further explore the adhesion effect of oligosaccharides on probiotic cells, the thallus of lactobacillus plantarum AUH2103 cultured in MRS medium was collected and resuspended in solutions containing fructo-oligosaccharides, galacto-oligosaccharides and 2' -fucosyllactose at different concentrations to prepare bacterial suspensions, and the adhesion ability of the bacterial suspensions to Caco-2 cells was measured, and the results are shown in Table 2.
TABLE 2 Effect of oligosaccharide addition after fermentation on the cell adhesion ability of Lactobacillus plantarum AUH2103
Note: different superscripts in the same column indicate significant differences (P < 0.05).
As can be seen from Table 2, the adhesion of Lactobacillus plantarum AUH2103, added with oligosaccharide after fermentation, to Caco-2 cells was significantly improved (P < 0.05) compared to the sugar-free control group. In the fructo-oligosaccharide group, the adhesion ability of Lactobacillus plantarum AUH2103 to Caco-2 cells is improved along with the increase of the concentration of the fructo-oligosaccharide, and the maximum number of viable bacteria after adhesion reaches 7.05 multiplied by 10 when 5g/L of the fructo-oligosaccharide is added 7 CFU/mL; in the galactooligosaccharide group, the adhesion capability of Lactobacillus plantarum AUH2103 to Caco-2 cells is reduced along with the increase of the concentration of galactooligosaccharide, and the maximum number of live bacteria after adhesion is 9.75 multiplied by 10 when 0.5g/L of galactooligosaccharide is added 7 CFU/mL; in the 2' -fucosyllactose group, the adhesion ability of Lactobacillus plantarum AUH2103 to Caco-2 cells is improved with the increase of the concentration of 2' -fucosyllactose, and the maximum viable count after adhesion is 7.80 × 10 when 5g/L of 2' -fucosyllactose is added 7 CFU/mL。
1.7 Effect of the addition of the composition on the adhesion of Lactobacillus plantarum AUH2103 to Caco-2 cells during incubation
According to the experimental result, 0.5g/L of galacto-oligosaccharide, 0.5g/L, 2g/L and 5g/L of fructo-oligosaccharide and 0.5g/L, 2g/L and 5g/L of 2' -fucosyllactose are selected for compounding. The compositional groups are shown in table 3.
TABLE 3 ratio of oligosaccharides in the groups of Complex oligosaccharides
The complex oligosaccharide solution was used to resuspend the Lactobacillus plantarum AUH2103 cells, and the adhesion of each group to Caco-2 cells was determined, with the results shown in Table 4.
TABLE 4 Effect of post-fermentation addition of the compositions of the present invention on the cell adhesion Capacity of Lactobacillus plantarum AUH2103
Note: different superscripts in the same column indicate significant differences (P < 0.05).
As can be seen from Table 4, the adhesion improving effect of group 2 on Lactobacillus plantarum AUH2103 was the best among all groups, and the number of viable cells after adhesion reached 1.45X 10 8 CFU/mL, significantly higher than other groups (P < 0.05). In addition, the groups 1 and 4 also have good promoting effect on the adhesion capability of the lactobacillus plantarum AUH2103, and the number of the live bacteria of the adhered group 1 is 1.34 multiplied by 10 8 CFU/mL, the number of viable bacteria after adhesion of group 4 was 1.25X 10 8 CFU/mL, all reach 10 8 CFU/mL.
Therefore, according to experimental results, the addition of the compound oligosaccharide after the fermentation of lactobacillus plantarum AUH2103 can significantly improve the cell adhesion capability of the strain, and when the content ratio of fructooligosaccharide, galactooligosaccharide and 2' -fucosyllactose is 1.
Example 2 use of the composition of the invention in infant formula
The viable count of the lactobacillus plantarum AUH2103 reaches 10 6 -10 7 And (3) CFU/g, the ratio of the added fructo-oligosaccharide, galactooligosaccharide and 2' -fucosyllactose is 1.
Example 3 use of the composition of the invention in probiotic solid beverages
The viable count of the lactobacillus plantarum AUH2103 reaches 10 8 -10 9 And (3) adding fructo-oligosaccharide, galactooligosaccharide and 2' -fucosyllactose in a ratio of 1.
Example 4 Complex oligosaccharide combination for improving adhesion of Lactobacillus rhamnosus MP108 to Caco-2 cells
1.1 Strain activation:
lactobacillus rhamnosus MP108 was stored in lyophilized powder form prior to the experiment. In the experiment, the strain is inoculated in MRS liquid culture medium for activation, and then is separated and purified on an MRS agar plate and is preserved by using a glycerol method. The cells were activated from glycerol storage tubes for use prior to each experiment.
1.2 culture Medium
Culture medium A: the culture medium of glucose in oligosaccharide MRS, wherein the concentration of oligosaccharide in the culture medium is as follows: fructo-oligosaccharide (MRS-FOS) 40g/L, galacto-oligosaccharide (MRS-GOS) 20g/L, 2 '-fucosyllactose (MRS-2' -FL) 20 g/L;
and (3) a culture medium B: adding oligosaccharide into MRS, wherein the concentration of the oligosaccharide in a culture medium is as follows: 40g/L fructo-oligosaccharide (MRS-FOS), 20g/L galacto-oligosaccharide (MRS-GOS), and 20 g/L2 '-fucosyllactose (MRS-2' -FL).
1.3 preparation of the strain suspension:
adding oligosaccharide before fermentation: after the strain is activated, the strain is respectively inoculated in a culture medium which replaces glucose in MRS by 40g/L fructo-oligosaccharide (MRS-FOS), 20g/L galacto-oligosaccharide (MRS-GOS) and 20 g/L2 '-fucosyllactose (MRS-2' -FL) according to the inoculation amount of 3 percent, and the culture medium which adds 40g/L fructo-oligosaccharide (MRS + FOS), 20g/L galacto-oligosaccharide (MRS + GOS) and 20 g/L2 '-fucosyllactose (MRS +2' -FL) is used as a control group in MRS, after 18h of culture, thalli are collected by centrifugation (10000 r/min,2 min), and washed by PBS for three times. Finally, resuspension was performed with PBS and adhesion assay was performed.
Oligosaccharide was added during incubation: after the strain is activated, the strain is inoculated in MRS culture medium according to the inoculation amount of 3 percent, after being cultured for 18 hours, the strain is collected by centrifugation (10000 r/min,2 min), and is washed 3 times by PBS. Finally, fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose with different concentrations or oligosaccharide combinations with different proportions are respectively added during the heavy suspension by PBS, and the order of magnitude of the viable bacteria number is adjusted to 10 9 CFU/mL, adhesion test.
1.4 cell adhesion assay:
the human colorectal adenocarcinoma cells Caco-2 are preserved in liquid nitrogen, subcultured after activation, and when the cells are stable, the Caco-2 cells are cultured until a compact monolayer membrane is formed, the cell morphology is good, the boundary is clear, and the cells are used for adhesion tests. Caco-2 cells were cultured at 2X 10 5 The concentration of individual cells/well was seeded in a 24-well cell culture plate at 5% CO 2 And 95% relative humidity and 37 ℃ until a monolayer of cells is formed. The monolayer cells were washed 2 times with PBS (pH 7.2) and 500. Mu.L of a lactic acid bacteria suspension (adjusted to a viable count of the order of 10) was added to each well 9 CFU/mL), 5% CO at 37 deg.C 2 And 95% relative humidity for 2h. The membrane was washed 3 times with PBS (pH 7.2) to remove unbound bacteria, 150. Mu.L of 0.25% trypsin digest was added, and after 15min of digestion at 37 ℃, 350. Mu.L of MEM medium supplemented with 10% fetal bovine serum was added to each well to stop digestion. Continuously diluting the mixture by 10 times of gradient, and detecting the number of viable bacteria by adopting a flat plate colony counting method, wherein the counted number of viable bacteria is the number of bacteria adhered to cells, and the number can reflect the strength of the adhesion capability of the bacteria to the cells under the condition that the number of the cells is the same.
1.5 Effect of oligosaccharide addition before fermentation on adhesion of Lactobacillus rhamnosus MP108 to Caco-2 cells
Lactobacillus rhamnosus MP108 thalli cultured in different oligosaccharide MRS culture media are collected to prepare bacterial suspension, and the adhesion capability of the bacterial suspension to Caco-2 cells is measured, and the results are shown in Table 1.
TABLE 5 Effect of oligosaccharide addition before fermentation on the adhesion of Lactobacillus rhamnosus MP108 cells
Note: different superscript letters in the same column indicate significant differences (P < 0.05).
As can be seen from Table 5, compared with the MRS group, in the three experimental groups for replacing oligosaccharides, the number of viable bacteria of all groups of Lactobacillus rhamnosus MP108 after adhering to Caco-2 cells is not obviously increased; in the addition group, the number of viable bacteria after adhesion is lower than that of the MRS control group. Therefore, the experimental results show that the addition of oligosaccharide or the replacement of oligosaccharide before fermentation cannot effectively improve the adhesion capability of lactobacillus rhamnosus MP108 to Caco-2 cells.
1.6 Effect of oligosaccharide addition on adherence of Lactobacillus rhamnosus MP108 to Caco-2 cells during incubation
In order to further explore the adhesion effect of oligosaccharides on probiotic cells, thallus of lactobacillus rhamnosus MP108 cultured in an MRS culture medium is collected and resuspended in solutions containing fructo-oligosaccharides, galacto-oligosaccharides and 2' -fucosyllactose at different concentrations to prepare bacterial suspensions, and the adhesion ability of the bacterial suspensions to Caco-2 cells is measured, and the results are shown in Table 2.
TABLE 6 Effect of oligosaccharide addition on the adhesion of Lactobacillus rhamnosus MP108 cells during incubation
Note: different superscripts in the same column indicate significant differences (P < 0.05).
As can be seen from Table 6, the adhesion energy of Lactobacillus rhamnosus MP108 oligosaccharide to Caco-2 cells was increased during incubation, as compared with the sugar-free control groupThe force is obviously improved (P is less than 0.05). In the fructo-oligosaccharide group, the viable count of Lactobacillus rhamnosus MP108 reaches 6.43 × 10 after adhesion when 5g/L of fructo-oligosaccharide is added 7 CFU/mL; in the galactooligosaccharide group, the adhesion capacity of the lactobacillus rhamnosus MP108 to Caco-2 cells is firstly increased and then decreased along with the increase of the concentration of the galactooligosaccharides, and the maximum number of adhered living bacteria is 6.13 multiplied by 10 when 2g/L of the galactooligosaccharides are added 7 CFU/mL; in the 2' -fucosyllactose group, the adhesion ability of Lactobacillus rhamnosus MP108 to Caco-2 cells decreases with the increase of the concentration of 2' -fucosyllactose, and the maximum viable count after adhesion is 5.68 × 10 when 0.5g/L of 2' -fucosyllactose is added 7 CFU/mL。
1.7 Effect of adding Complex oligosaccharide on adhesion of Lactobacillus rhamnosus MP108 to Caco-2 cells during incubation
According to the experimental results, 5g/L of fructo-oligosaccharide is selected to be compounded with 0.5g/L, 2g/L and 5g/L of galacto-oligosaccharide and 2' -fucosyllactose. The compositional groups are shown in table 7:
TABLE 7 oligosaccharide ratios in the Compound oligosaccharides groups
The complex oligosaccharide solution was used to resuspend lactobacillus rhamnosus MP108 cells, and the adhesion of each group to Caco-2 cells was determined, with the results shown in table 8.
TABLE 8 Effect of Compound oligosaccharide addition on the cell adhesion ability of Lactobacillus rhamnosus MP108 during incubation
Note: different superscript letters in the same column indicate significant differences (P < 0.05).
As can be seen from Table 8, in all groups, group 1 showed the best effect of improving the adhesion of Lactobacillus rhamnosus MP108, and the viable count after adhesion reached 1.29X 10 8 CFU/mL is improved by 14 times and is obviously higher than other groups (P is less than 0.05); the improvement degree of group 4 is also higher, reaching 9 times. In addition, the regulating capability of other groups on the adhered cells of the lactobacillus rhamnosus MP108 is similar, and the number of the adhered living bacteria reaches 10 7 CFU/mL.
Therefore, according to experimental results, the in vitro adhesion capacity of the lactobacillus rhamnosus MP108 to Caco-2 cells can be remarkably improved by adding the compound oligosaccharide during incubation of the lactobacillus rhamnosus MP108, wherein the number of adhered live bacteria of the lactobacillus rhamnosus MP108 in group 1 is the highest, namely the content of fructo-oligosaccharide is 5g/L, the content of galacto-oligosaccharide is 0.5-2.0g/L, the content of 2' -fucosyllactose is 0.5g/L, and the ratio is 10 (1-4): 1.
Example 5
Lactobacillus rhamnosus MP108 and the oligosaccharide composition of the invention are used in infant formula. The viable count of the lactobacillus rhamnosus MP108 reaches 10 6 -10 7 CFU/g, the ratio of the added fructo-oligosaccharide, galacto-oligosaccharide and 2' -fucosyllactose is 10 (1-4) to 1, and the total amount of oligosaccharide added per 100g of milk powder is 4-8g.
Example 6
Lactobacillus rhamnosus MP108 and the oligosaccharide composition of the invention are applied to probiotic solid beverages. The viable count of the lactobacillus rhamnosus MP108 reaches 10 8 -10 9 CFU/g, the ratio of the added fructo-oligosaccharide, the added galacto-oligosaccharide and the 2' -fucosyllactose is 10 (1-4) to 1, and the total amount of the added oligosaccharide is 0.4-0.6g per 1g of the probiotic solid beverage.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that it is obvious to those skilled in the art that various modifications and improvements can be made without departing from the principle of the present invention, and these modifications and improvements should also be considered as the protection scope of the present invention.
Claims (9)
1. A composition comprising fructooligosaccharides, galactooligosaccharides and 2' -fucosyllactose; the mass ratio of the fructo-oligosaccharide, the galacto-oligosaccharide and the 2' -fucosyllactose is (1-10) to (1-4).
2. The composition according to claim 2, wherein the mass ratio of fructooligosaccharide, galactooligosaccharide and 2' -fucosyllactose is 1.
3. The composition of claim 1, further comprising a probiotic.
4. The composition according to claim 3, characterized in that the probiotic bacteria comprise Lactobacillus rhamnosus and/or Lactobacillus plantarum; the lactobacillus rhamnosus is preferably an MP108 strain, and the lactobacillus plantarum is preferably an AUH2103 strain.
5. Use of a composition according to any one of claims 1 to 4 in the manufacture of a product for promoting gut health and increasing intestinal probiotic colonization.
6. The use according to claim 5, wherein the probiotic bacteria comprise at least one of Lactobacillus rhamnosus, lactobacillus plantarum.
7. The use according to claim 5, wherein the composition increases the ability of the probiotic to adhere to Caco-2 cells.
8. Use according to claim 5, wherein the product comprises infant formula, special medical use formula, nutraceutical, probiotic solid drink, fermented product.
9. A product for promoting gut health comprising the composition of any one of claims 1 to 4 and a food and/or nutraceutical acceptable vehicle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211630783.2A CN115868631A (en) | 2022-12-19 | 2022-12-19 | Composition for promoting intestinal health and application and product thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211630783.2A CN115868631A (en) | 2022-12-19 | 2022-12-19 | Composition for promoting intestinal health and application and product thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115868631A true CN115868631A (en) | 2023-03-31 |
Family
ID=85753940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211630783.2A Pending CN115868631A (en) | 2022-12-19 | 2022-12-19 | Composition for promoting intestinal health and application and product thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115868631A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014210718A (en) * | 2013-04-18 | 2014-11-13 | 独立行政法人農業・食品産業技術総合研究機構 | Intestinal barrier function-improving agent |
| CN109528777A (en) * | 2018-12-25 | 2019-03-29 | 东北农业大学 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
| CN111838683A (en) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | Prebiotic composition containing human milk oligosaccharide and application thereof |
| CN114262680A (en) * | 2022-01-04 | 2022-04-01 | 澳优乳业（中国）有限公司 | Bacterial strain and application thereof |
| CN114390897A (en) * | 2021-10-29 | 2022-04-22 | 海普诺凯营养品有限公司 | Composition of prebiotics and probiotics and application thereof |
-
2022
- 2022-12-19 CN CN202211630783.2A patent/CN115868631A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014210718A (en) * | 2013-04-18 | 2014-11-13 | 独立行政法人農業・食品産業技術総合研究機構 | Intestinal barrier function-improving agent |
| CN109528777A (en) * | 2018-12-25 | 2019-03-29 | 东北农业大学 | By the application for the composition that Lactobacillus rhamnosus and 2`- fucosyllactose form |
| CN111838683A (en) * | 2020-07-30 | 2020-10-30 | 黑龙江省完达山乳业股份有限公司 | Prebiotic composition containing human milk oligosaccharide and application thereof |
| CN114390897A (en) * | 2021-10-29 | 2022-04-22 | 海普诺凯营养品有限公司 | Composition of prebiotics and probiotics and application thereof |
| CN114262680A (en) * | 2022-01-04 | 2022-04-01 | 澳优乳业（中国）有限公司 | Bacterial strain and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| AILI LI 等: "2′-Fucosyllactose promotes Lactobacillus rhamnosus KLDS 8001 to repair LPS-induced damage in Caco-2 cells", FOOD BIOCHEMISTRY, pages 1 - 12 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9596876B2 (en) | Method for stimulating the intestinal flora | |
| CN112375727B (en) | Application of lactoferrin in promoting proliferation of bifidobacteria and lactobacilli | |
| EP2117355A1 (en) | Method of improving skills with a composition comprising non-digestible saccharide | |
| CN113519849B (en) | Breast milk oligosaccharide for improving intestinal tract resistance to escherichia coli infection and application thereof | |
| CN112869170B (en) | Probiotics prebiotic nutritional composition capable of improving gastrointestinal tract immunity and application | |
| AU2007231917A1 (en) | Anti-Allergy Lactic Acid Bacteria | |
| CN113913322A (en) | Application of bifidobacterium lactis BLA80 in relieving diarrhea and improving intestinal immunity | |
| JP2023537608A (en) | Human milk oligosaccharide composition for use in bacteriotherapy | |
| CN111000244A (en) | Lactobacillus casei capable of improving intestinal health and application thereof | |
| EP3722413A1 (en) | Novel bifidobacterium bacteria and composition including novel bifidobacterium bacteria | |
| CN115868631A (en) | Composition for promoting intestinal health and application and product thereof | |
| CN113712207B (en) | Probiotic prebiotic composition for improving gastrointestinal tract immunity and application thereof | |
| TW202325835A (en) | Enhancement of gastrointestinal barrier function with a combination of lactic acid bacteria strains | |
| CN116531411A (en) | Use of lactic acid bacteria strains in combination to enhance gastrointestinal barrier function | |
| CN114568516A (en) | Composition containing bifidobacterium longum subsp. infantis and breast milk oligosaccharide and application thereof | |
| CN114246339A (en) | Composition and application thereof in preparation of product for improving intestinal immunity | |
| CN114568520A (en) | Infant formula powder containing bifidobacterium longum subspecies infantis and application thereof | |
| CN115836733A (en) | Application of oligosaccharide in preparation of product for regulating intestinal flora | |
| CN114287629A (en) | Composition and product for improving intestinal immunity | |
| CN114568701B (en) | Composition containing fructo-oligosaccharide and probiotics and application thereof | |
| CN115354009B (en) | Bifidobacterium longum subspecies neonatorum with pili and application thereof | |
| CN117337992B (en) | Probiotic prebiotic composition and application thereof | |
| US20220395011A1 (en) | Synergistic blends of probiotics expressing improved beneficial activity for human host favourably interacting with food, particularly baby food | |
| KR102428864B1 (en) | Novel Bifidobacterium longum TSB-L1 with xylooligosaccharide specific availability | |
| CN117070398B (en) | Bifidobacterium animalis subspecies Bi66 for improving constipation and application, product and method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |